Health (PRISME)
- Presentation
- Activities
- Members
- Publications
The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.
Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.
One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.
The activities can be divided into three research areas:
Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.
Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.
Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.
NON-PERMANENTS:
- DOCTORANTS / DOCTORAL STUDENTS:
- CHERCHEURS NON-PERMANENTS / NON-PERMANENT RESEARCHERS:
- M. Gouzevitch, Fabienne Lagarde, I. Laktineh, V. Buridon, X. Chen, et al.. High rate, fast timing Glass RPC for the high
CMS muon detectors. XIII Workshop on Resistive Plate Chambers and Related Detectors, Feb 2016, Ghent, Belgium. ⟨in2p3-01327074⟩ - J. Billard. Search for low-mass WIMPs with the EDELWEISS-III experiment. UCLA Dark Matter 2016, Feb 2016, Los Angeles, United States. ⟨hal-02060032⟩
- N. Galy, N. Toulhoat, N. Moncoffre, N. Bérerd, Y. Pipon, et al.. Behavior of
C in irradiated nuclear graphite waste: consequences for inventory, decontamination and disposal. International Symposium on PREparation for DECommissioning (PREDEC), Feb 2016, Lyon, France. ⟨in2p3-02096050⟩ - Shady Kotb, François Lux, Claire Rodriguez-Lafrasse, Olivier Tillement, Lucie Sancey. Nanoparticle Enhanced MRI-Guided Radiation Therapy: Final proof of concept before phase I trial.. ICTR-PHE 2016, Feb 2016, Genève, Switzerland. ⟨hal-01275090⟩
- N. Krah, M. Testa, I. Rinaldi. Improved patient-specific optimization of the stopping power calibration for proton therapy planning using a single optimized proton radiography. ICTR-PHE 2016, Feb 2016, Genève, Switzerland. ⟨hal-01276427⟩
- B. Huisman, Jean Michel Létang, E. Testa, D. Sarrut. Accelerated Prompt Gamma estimation for clinical Proton Therapy simulations. International Conference on Translational Research in Radio-Oncology | Physics for Health in Europe (ICTR-PHE 2016), Feb 2016, Genève, Switzerland. . ⟨hal-01276369⟩
- J.M. Letang, W. El Kanawati, D. Dauvergne, M. Pinto, D. Sarrut, et al.. Monte Carlo simulation of prompt-γ emission in proton therapy using a track length estimator. ICTR-PHE 2016, Feb 2016, Genève, Switzerland. ⟨hal-01276435⟩
- M. Cunha, C. Monini, E. Testa, M. Beuve. NanoxTM: A new multiscale theoretical framework to predict cell survival in the context of particle therapy. ICTR-PHE 2016, Feb 2016, Genève, Switzerland. ⟨hal-01276353⟩
- M. Cunha, E. Testa, M. Beuve, J. Balosso, A. Chaikh. Evaluation of the size of micrometric/nanometric dosimeters for use in radiotherapy and medical physics. ICTR-PHE 2016, Feb 2016, Genève, Switzerland. ⟨hal-01276322⟩
- A. Wozny, A. Lauret, Y. Saintigny, P. Battiston-Montagne, M. Beuve, et al.. HIF-1α plays a key role in the response of HNSCC cancer stem cells to photon and carbon ion exposures. ICTR-PHE 2016, Feb 2016, Genève, Switzerland. pp.S115. ⟨hal-01276470⟩
Powered by HAL 